How in the world can Mannkind be listed amongst "5" companies dominating diabetes when the current share price is a 1.93. Come on Mann!
Motley Fool realizes the tremendous potential that Afrezza has.
More new shareholders every day.
It's obvious that they expect Afrezza to be in the game.
Mannkind/Afrezza is starting to gain recognition.
"The diabetes market currently includes products from Novo Nordisk (NYSE: NVO ) , Sanofi (NYSE: SNY ) , MannKind (Nasdaq: MNKD ) , and the diabetes partnership of Bristol-Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) ."
it's a buy.. but they have had reconginition for 4 years.